Testicular Disorders
Also known as: Macro, Large, Adenoma, Adenomatous, Tumor
Methodology & AI Transparency ⓘ
Testicular Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Testicles, or testes, make male hormones and sperm.
- 2 Real-world patient consensus: Synonyms for Testicular Disorders (R39.89): Macro, Large, Adenoma (Skin & Dermatology).
- 3 Typical cash cost range: Clinicians assessing Testicular Disorders focus on epidermal barrier filaggrin/ceramide in Testicular Disorders (R39.89: disruption) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Testicular Disorders: Affected Body Surface in Testicular Disorders (R39.89: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (R39.89)) and Fasting Lipids & in Testicular Disorders (R39.89: ALT (if systemic).
Ask our AI Specialists anything about Testicular Disorders
What Is Testicular Disorders?
Testicles, or testes, make male hormones and sperm. They are two egg-shaped organs inside the scrotum, the loose sac of skin behind the penis. It's easy to injure your testicles because they are not protected by bones or muscles. Men and boys should wear athletic supporters when they play sports. You should examine your testicles monthly and seek medical attention for lumps, redness, pain or other changes. Testicles can get inflamed or infected. They can also develop cancer. Testicular cancer is rare and highly treatable. It usually happens between the ages of 15 and 40.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Testicular Disorders (ICD-10 R39.89) is driven by epidermal barrier filaggrin/ceramide in Testicular Disorders (R39.89: disruption); Cross-referenced with NIH MeSH (Testicular Diseases), specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Fasting Lipids & in Testicular Disorders (R39.89: ALT (if systemic) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Testicular Disorders (R39.89): persistent erythematous plaques, in Testicular Disorders (R39.89: scaly patches, pruritic)
- • Secondary Testicular Disorders clinical sign: compromised epidermal barrier in Testicular Disorders (R39.89: with dryness, fissuring,)
- • Symptom flares in Testicular Disorders correlating with Affected Body Surface in Testicular Disorders (R39.89: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (R39.89)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Testicular Disorders (R39.89: morphology exam) evaluation (R39.89)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Testicular Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R39.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Testicular Disorders (R39.89: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (R39.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Testicular Disorders (R39.89: ALT (if systemic) | Within baseline reference limits (R39.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Testicular Disorders (R39.89: & hs-CRP) | 25(OH)D 40–65 ng/mL (R39.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Testicular Disorders
Treatment selection for Testicular Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Testicular Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Glucagon-like peptide 1 receptor agonists on testicular: What a 680-Participant Study Found Our systematic review and meta-analysis suggest a possible role for GLP-1RAs in the therapy of functional hypogonadism related to overweight and obesity, while also promoting weight loss. Andrology • 2025-11-15 • Meta-Analysis | N = 680 | 91/100 | PMID 40105090 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of short-term oral phytoestrogen supplementation on the Phytoestrogen treatment interferes with HPT axis in CaP patients by inducing testicular resistance to LH and compensated hypogonadism. The Prostate • 2006-07-01 • Randomized Controlled Trial | N = 40 | 88/100 | PMID 16637075 ↗ |
| What the Latest Evidence Really Says About Testosterone deficiency in testicular cancer survivors - a systematic review and Strong evidence exists that standard CT, non-conventional therapy and infradiaphragmatic RT are associated with an increased risk of TD in TGCC-patients when compared with orchiectomy alone. Andrology • 2016-05-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 27009402 ↗ |
Testicular Disorders Patient Community & “People Like Me” Threads
Filter Testicular Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.